Dados do Resumo

Título

Molecular characterization of in vitro models of adenoid cystic carcinoma

Introdução

Adenoid cystic carcinoma (ACC) is a malignant tumor of the salivary gland that is characterized by slow progression and low survival rates. There is no consensus on the use of chemotherapy, and small patient cohorts limit the development of clinical trials. The use of in vitro and in vivo models allows us to understand oncogenesis and define personalized therapies, but molecular characterization is necessary to use these models.

Objetivo

The aim of this study is to evaluate the presence of the MYB-NFIB fusion in primary cultures and samples of adenoid cystic carcinoma by RT-PCR and evaluation of MYB protein expression by immunohistochemistry and its association with the presence of the MYB-NFIB fusion.

Métodos

Fifteen adenoid cystic carcinoma samples from the A.C.Camargo Cancer Center Biobank and 5 established cell lines will be analyzed. After RNA extraction and cDNA synthesis, RT-PCR will be performed to detect the MYB-NFIB fusion; the products will be visualized by agarose gel electrophoresis. MYB protein expression will be evaluated on FFPE tissue samples from the same patients. Immunohistochemistry will be evaluated qualitatively and semi-quantitatively, based on the number and intensity of the stained cells. Comparison of clinical data and MYB protein expression and MYB-NFIB fusion will be performed by the Chi-square or Fisher’s exact test. Survival curves will be estimated by Kaplan-Meier and compared by the log-rank test, adopting a significance level of 5%. Statistical analyses will be performed using SPSS software (CEP protocol 2624/18).

Resultados

This study aims to characterize and validate in vitro models of adenoid cystic carcinoma established in our research group and verify the relationship between MYB protein expression and the presence of MYB-NFIB fusion in the analyzed samples.

Conclusões

Validation of in vitro models for the study of adenoid cystic carcinoma will allow a better understanding of the molecular basis of the disease and the design and evaluation of the use of personalized therapies.

Financiador do resumo

Adenoid Cystic Carcinoma Research Foundation (ACCRF), CNPq.

Palavras Chave

Adenoid Cystic Carcinoma; MYB-NFIB fusion; MYB protein